Shares in ThromboGenics NV reached an all-time during early trading Tuesday on news that its lead drug candidate, microplasmin, reached the primary endpoint in the first of two Phase III trials in the treatment of symptomatic focal vitreomacular adhesion (VMA). (BioWorld International) Read More
